Le quote di ricavo sono stime per nine months ended September 30, 2026, non cifre tratte da un documento depositato.
SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.
SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.
Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.
Costruito dai documenti depositati da Biogen Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
253,51 USD+1,2%chiusura 13 nov
Dati fino al 30 settembre 2026, dal 10-Q depositato il 28 ottobre 2026
Biogen sells prescription medicines for multiple sclerosis and rare diseases, including SPINRAZA for spinal muscular atrophy, through health-care providers.
Just reported
From Biogen's results release of 28 ottobre 2026; its quarterly report has since been filed.
Actual
2,8B USD
+11% y/y
+2,5% q/q
Guided
—
No guide given
Actual
-0,14 USD
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 40 dello storico dei voti di Biogen Inc.. Gli altri 38 risalgono fino a ottobre 2016.
